Emerging Modes-of-action in Drug Discovery

Overview

Journal Medchemcomm

Publisher Royal Society of Chemistry

Specialty Chemistry

Date 2019 Nov 2

PMID 31673315

Citations 10

Authors

Eric Valeur

Frank Narjes

Christian Ottmann

Alleyn T Plowright

Affiliations

Soon will be listed here.

Abstract

An increasing focus on complex biology to cure diseases rather than merely treat symptoms has transformed how drug discovery can be approached. Instead of activating or blocking protein function, a growing repertoire of drug modalities can be leveraged or engineered to hijack cellular processes, such as translational regulation or degradation mechanisms. Drug hunters can therefore access a wider arsenal of modes-of-action to modulate biological processes and this review summarises these emerging strategies by highlighting the most representative examples of these approaches.

Citing Articles

Development of Oligomeric Mannose-6-phosphonate Conjugates for Targeted Protein Degradation.

Stevens C, Zhou Y, Teng P, Rault L, Liao Y, Tang W ACS Med Chem Lett. 2023; 14(6):719-726.

PMID: 37312839 PMC: 10258825. DOI: 10.1021/acsmedchemlett.2c00479.

It's ok to be outnumbered - sub-stoichiometric modulation of homomeric protein complexes.

Dimitrova Y, Gutierrez J, Huard K RSC Med Chem. 2023; 14(1):22-46.

PMID: 36760737 PMC: 9890894. DOI: 10.1039/d2md00212d.

Characterization of a new fusicoccane-type diterpene synthase and an associated P450 enzyme.

Huang J, Lv J, Xiao L, Xu Q, Lin F, Wang G Beilstein J Org Chem. 2022; 18:1396-1402.

PMID: 36262672 PMC: 9551204. DOI: 10.3762/bjoc.18.144.

Fusicoccin-A Targets Cancerous Inhibitor of Protein Phosphatase 2A by Stabilizing a C-Terminal Interaction with 14-3-3.

Brink H, van Senten J, De Vries-van Leeuwen I, da Costa Pereira D, Piersma S, Jimenez C ACS Chem Biol. 2022; 17(11):2972-2978.

PMID: 36255265 PMC: 9679992. DOI: 10.1021/acschembio.2c00299.

Identification of molecular glues of the SLP76/14-3-3 protein-protein interaction.

Soini L, Redhead M, Westwood M, Leysen S, Davis J, Ottmann C RSC Med Chem. 2021; 12(9):1555-1564.

PMID: 34667951 PMC: 8459327. DOI: 10.1039/d1md00172h.

References

Ballone A, Centorrino F, Wolter M, Ottmann C . Structural characterization of 14-3-3ζ in complex with the human Son of sevenless homolog 1 (SOS1). J Struct Biol. 2018; 202(3):210-215. DOI: 10.1016/j.jsb.2018.01.011. View

Jagemann L, Perez-Rivas L, Josue Ruiz E, Ranea J, Sanchez-Jimenez F, Nebreda A . The functional interaction of 14-3-3 proteins with the ERK1/2 scaffold KSR1 occurs in an isoform-specific manner. J Biol Chem. 2008; 283(25):17450-62. DOI: 10.1074/jbc.M709185200. View

Crews C, Georg G, Wang S . Inducing Protein Degradation as a Therapeutic Strategy. J Med Chem. 2016; 59(11):5129-30. DOI: 10.1021/acs.jmedchem.6b00735. View

Jones L . Small-Molecule Kinase Downregulators. Cell Chem Biol. 2017; 25(1):30-35. DOI: 10.1016/j.chembiol.2017.10.011. View

Liu S, Yosief H, Dai L, Huang H, Dhawan G, Zhang X . Structure-Guided Design and Development of Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitors. J Med Chem. 2018; 61(17):7785-7795. PMC: 6309379. DOI: 10.1021/acs.jmedchem.8b00765. View

Shen C, Yuan P, Perez-Lorenzo R, Zhang Y, Lee S, Ou Y . Phosphorylation of BRAF by AMPK impairs BRAF-KSR1 association and cell proliferation. Mol Cell. 2013; 52(2):161-72. PMC: 3892895. DOI: 10.1016/j.molcel.2013.08.044. View

Mullard A . Longer-lasting HIV drugs. Nat Rev Drug Discov. 2019; 18(9):656. DOI: 10.1038/d41573-019-00141-5. View

Ory S, Zhou M, Conrads T, Veenstra T, Morrison D . Protein phosphatase 2A positively regulates Ras signaling by dephosphorylating KSR1 and Raf-1 on critical 14-3-3 binding sites. Curr Biol. 2003; 13(16):1356-64. DOI: 10.1016/s0960-9822(03)00535-9. View

Boriack-Sjodin P, Ribich S, Copeland R . RNA-modifying proteins as anticancer drug targets. Nat Rev Drug Discov. 2018; 17(6):435-453. DOI: 10.1038/nrd.2018.71. View

10.

Muda K, Bertinetti D, Gesellchen F, Hermann J, von Zweydorf F, Geerlof A . Parkinson-related LRRK2 mutation R1441C/G/H impairs PKA phosphorylation of LRRK2 and disrupts its interaction with 14-3-3. Proc Natl Acad Sci U S A. 2013; 111(1):E34-43. PMC: 3890784. DOI: 10.1073/pnas.1312701111. View

11.

Kariko K, Muramatsu H, Welsh F, Ludwig J, Kato H, Akira S . Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. 2008; 16(11):1833-40. PMC: 2775451. DOI: 10.1038/mt.2008.200. View

12.

Bier D, Rose R, Bravo-Rodriguez K, Bartel M, Ramirez-Anguita J, Dutt S . Molecular tweezers modulate 14-3-3 protein-protein interactions. Nat Chem. 2013; 5(3):234-9. DOI: 10.1038/nchem.1570. View

13.

Rizvi N, Howe J, Nahvi A, Klein D, Fischmann T, Kim H . Discovery of Selective RNA-Binding Small Molecules by Affinity-Selection Mass Spectrometry. ACS Chem Biol. 2018; 13(3):820-831. DOI: 10.1021/acschembio.7b01013. View

14.

Rizvi N, Smith G . RNA as a small molecule druggable target. Bioorg Med Chem Lett. 2017; 27(23):5083-5088. DOI: 10.1016/j.bmcl.2017.10.052. View

15.

Fan X, Jin W, Lu J, Wang J, Wang Y . Rapid and reversible knockdown of endogenous proteins by peptide-directed lysosomal degradation. Nat Neurosci. 2014; 17(3):471-80. PMC: 3937121. DOI: 10.1038/nn.3637. View

16.

Fischer A, Baljuls A, Reinders J, Nekhoroshkova E, Sibilski C, Metz R . Regulation of RAF activity by 14-3-3 proteins: RAF kinases associate functionally with both homo- and heterodimeric forms of 14-3-3 proteins. J Biol Chem. 2008; 284(5):3183-3194. DOI: 10.1074/jbc.M804795200. View

17.

Zhou B, Hu J, Xu F, Chen Z, Bai L, Fernandez-Salas E . Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression. J Med Chem. 2017; 61(2):462-481. PMC: 5788414. DOI: 10.1021/acs.jmedchem.6b01816. View

18.

Sheard L, Tan X, Mao H, Withers J, Ben-Nissan G, Hinds T . Jasmonate perception by inositol-phosphate-potentiated COI1-JAZ co-receptor. Nature. 2010; 468(7322):400-5. PMC: 2988090. DOI: 10.1038/nature09430. View

19.

Ottis P, Crews C . Proteolysis-Targeting Chimeras: Induced Protein Degradation as a Therapeutic Strategy. ACS Chem Biol. 2017; 12(4):892-898. DOI: 10.1021/acschembio.6b01068. View

20.

Valeur E, Gueret S, Adihou H, Gopalakrishnan R, Lemurell M, Waldmann H . New Modalities for Challenging Targets in Drug Discovery. Angew Chem Int Ed Engl. 2017; 56(35):10294-10323. DOI: 10.1002/anie.201611914. View